Charlie's Holdings Reports 58% Revenue Growth to $15.5 Million for First Half 2022

Author's Avatar
Aug 15, 2022

Charlie's best-selling e-liquids are in Substantive Review with the FDA and remain in the select minority of 2020 PMTA submissions that are still viable; the Company submitted PMTAs for more than 700 additional products prior to the May 14, 2022 FDA deadline.